Last reviewed · How we verify
Low-dose anrikefon
Anrikefon is an interferon-alpha derivative that enhances innate immune responses and has antiviral and antiproliferative properties.
Anrikefon is an interferon-alpha derivative that enhances innate immune responses and has antiviral and antiproliferative properties. Used for Chronic hepatitis B, Chronic hepatitis C, Certain viral infections.
At a glance
| Generic name | Low-dose anrikefon |
|---|---|
| Also known as | Low-dose anrikefon-based patient-controlled analgesia |
| Sponsor | Peking University First Hospital |
| Drug class | Interferon-alpha analog |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology |
| Phase | FDA-approved |
Mechanism of action
Anrikefon acts as an interferon-alpha (IFN-α) analog, which binds to interferon-alpha receptors on cell surfaces to activate JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, and increased antigen presentation. The drug exhibits antiviral, antiproliferative, and immunomodulatory effects.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Certain viral infections
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Leukopenia
- Thrombocytopenia
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose anrikefon CI brief — competitive landscape report
- Low-dose anrikefon updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI